A Phase 2/3 interventional study of CABA-201 and CABA-201 in Systemic Sclerosis, Scleroderma and Interstitial Lung Diseases, sponsored by Cabaletta Bio. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Cabaletta Bio · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 66th largest by planned enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2024, is one of 5 in phase 2/3, reaches primary completion later than 41 of the 51 other live ones, and was the 127th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 37 is close to the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
Cabaletta Bio is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Cabaletta Bio has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Systemic sclerosis (SSc), also known as scleroderma , is a rare autoimmune disorder characterized by autoantibody production and abnormal B cell function. Though the cause of SSc is not well understood, it is thought to involve B cells that cause the body to attack different tissues in one's own body, causing skin and organ fibrosis. This study is being conducted to evaluate the safety and efficacy of an investigational therapy, CABA-201, a CD19-CAR T cell therapy, that can be given to patients with SSc who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Severe Skin Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with severe skin involvement Organ Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with organ involvement
Biological: CABA-201
Infusion of CABA-201 with preconditioning in subjects with SSc
Biological: CABA-201
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Also known as: Rese-cel, Resecabtagene autoleucel
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Also known as: Rese-cel, Resecabtagene autoleucel
Phase 1/2: To evaluate incidence of adverse events
Incidence and severity of AEs
Time frame: Up to 28 days after CABA-201 infusion
Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects
Mean change from baseline in % predicted FVC without any immunomodulatory or anti-fibrotic medications and on no or low dose of steroids
Time frame: Week 52
To evaluate adverse events and laboratory abnormalities
Incidence and severity of AEs, including changes in laboratory values and vital signs
Time frame: Up to 156 weeks (Phase 1/2) and through 104 weeks (Sub-study)
To characterize the pharmacodynamics (PD)
Levels of B cells in the blood
Time frame: Up to 156 weeks (Phase 1/2) and through 104 weeks (Sub-study)
To characterize the pharmacokinetics (PK)
Levels of CABA-201-positive T cells in the blood
Time frame: Up to 156 weeks (Phase 1/2) and through 104 weeks (Sub-study)
To evaluate efficacy
Proportion of subjects achieving revised Composite Response Index for Systemic Sclerosis (CRISS) criteria
Time frame: Up to 156 weeks (Phase 1/2) and at Week 52 (Sub-study)
Mean change from baseline in Modified Rodnan Skin Score (mRSS)
Time frame: Week 52 (Sub-study)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jul 2029, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Anti-CD19 CAR-T Cells CABA-201
Cabaletta Bio